分子量:52 kDa

纯度:95% as determined by SDS-PAGE.

内毒素:Less than 1.0 EU per μg of the Cynomolgus B7-2, Fc Tag by the LAL method.

Buffer:50 mM tris, 100 mM glycine, pH7.5

生物活性:Measured by its binding ability in a functional ELISA. Immobilized Cynomolgus CTLA-4, His Tag (Catalog # CT4-C5227) at 2 μg/mL ( 100 μl/well ) can bind Cynomolgus B7-2, Fc Tag (Catalog # CD6-C5254) with a linear range of 0.01-0.1 μg/mL.

产品特性:Cynomolgus B7-2, Fc Tag is fused with a human IgG1 Fc tag at the C-terminus, and has a calculated MW of 52 kDa. The predicted N-terminus is Ala 19. The reducing (R) protein migrates as 80-110 kDa in SDS-PAGE  due to glycosylation.

产品背景:Cluster of Differentiation 86 (CD86) is also known as B-lymphocyte activation antigen B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily, and is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B72 is expressed at low levels on monocytes and can be upregulated through interferon γ. CD86 is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD86 works in tandem with CD80 to prime T cells. Recent study has revealed that B7-2 promotes the generation of a mature APC repertoire and promotes APC function and survival. Furthermore, the B7 proteins are also involved in innate immune responses by activating NF-κB-signaling pathway in macrophages. CD86 thus is regarded as a promising candidate for immune therapy. CD86+ macrophages in Hodgkin lymphoma patients are an independent marker for potential nonresponse to firstline-therapy.